Business Wire

IPROOV

Share
iProov Face Verification Selected by itsme® to Support Global Expansion

British company iProov has today announced that European digital identity leader, itsme®, has selected iProov’s Genuine Presence Assurance® technology to support its global expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419006005/en/

Launched in 2017 by qualified trust service provider, Belgian Mobile ID, itsme® is Belgium's digital identity app. It is currently used by more than 35% of the Belgian population and is relied on by more than 150 companies in the private sector (banks, insurance companies etc) and by the Belgian government. From now, users in the Netherlands will also have access to itsme®’s trusted ID solution and will be able to securely authenticate themselves and onboard to digital services. iProov will verify the faces of new users, whatever their mobile device.

“We needed a technology partner to support our mission to make secure digital identities available to everyone. iProov was the obvious choice. They hold privacy and security in the highest regard and offer the future-proof, cutting-edge technology that will enable us to identify users internationally,” Stephanie De Bruyne, CEO at itsme, said.

Onboarding for an eIDAS level high or qualified signature has to meet very demanding, independently audited and certified international standards. Previously, these could only be met by an in-person meeting or video calling. itsme® avoids these expensive and tedious methods by using iProov’s faster, more convenient, less costly and more secure solution.

iProov’s Genuine Presence Assurance technology enables users to onboard to the itsme® service in a way that is both secure and effortless to use. A user scans their identity document using their mobile device. They then scan their face in a process that takes a few brief seconds. iProov technology ensures that the user is the right person, matching the identity in the document, that they are a real person, and that they are authenticating right now. The iProov process maximizes inclusiveness by eliminating the need for users to follow instructions to move or read out words.

Andrew Bud, Founder and CEO of iProov, said: “We are delighted to be working with itsme®, a true pioneer in the provision of digital identity trust services. I have huge respect for how itsme® has successfully driven the uptake of digital identity in Belgium, so it’s a pleasure and privilege to be partnering on a solution for the Netherlands. This is yet another demonstration that iProov is the technology of choice for Europe’s leading eIDAS providers.”

itsme® enables identification, secure onboarding, authentication on website or app, confirmation of transactions and qualified electronic signatures, all to the highest level of security. itsme® was granted accreditation by the Belgian government as an official form of digital identity in 2018 and on a European level in 2019 (LOA high eIDAS).

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance®, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

About itsme®

Since its launch in 2017, the itsme® app has become the widely accepted simple and secure standard for mobile identification and the protection of privacy in the digital world. itsme® enables the following: identification (creating a new online account and sharing identity details), authentication (secure, personal access to a website or application), confirmation of a transaction (approval of an order or bank payment) and, finally, the legally binding electronic signing of documents (qualified electronic signature with the highest level of security). itsme® was granted accreditation by the Belgian government as an official form of digital identity in January 2018 and on a European level in December 2019 (LOA high eIDAS). The itsme® app is used extensively in the financial sector among others because it complies with PSD2, FATF and GDPR guidelines. It has also been awarded ISO27001 certification.

itsme® was developed by the Belgian Mobile ID consortium, which combines the seven Belgian market leaders from the banking and telecommunications sectors: Belfius, BNP Paribas Fortis, CBC/KBC & ING, on the one hand, and Orange Belgium, Proximus and Telenet on the other. itsme® takes the security of the electronic identity card to the world of mobile.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye